Copyright
©The Author(s) 2024.
World J Gastrointest Pharmacol Ther. Sep 5, 2024; 15(5): 97330
Published online Sep 5, 2024. doi: 10.4292/wjgpt.v15.i5.97330
Published online Sep 5, 2024. doi: 10.4292/wjgpt.v15.i5.97330
Table 1 Patient characteristics at baseline (n = 70), n (%)
Demographics | KiwiBiotic | Psyllium husk | Total | P value |
Gender | 0.138a | |||
Female | 25 (71.43) | 19 (54.29) | 44 (62.86) | |
Male | 10 (28.57) | 16 (45.71) | 26 (37.14) | |
Age (year) | 0.156 | |||
Mean (SD) | 41.4 (10.96) | 45.83 (14.84) | 43.61 (13.14) | |
Range | 18-65 | 23-73 | 18-73 | |
Weight (kg) | 0.064 | |||
Mean (SD) | 58.89 (7.88) | 62.41 (8.03) | 60.65 (8.092) | |
Range | 42-80.9 | 47-79.3 | 42-80.9 | |
Height (m) | 0.123 | |||
Mean (SD) | 162.1 (6.68) | 164.73 (7.54) | 163.42 (7.2) | |
Range | 152-176.7 | 152-177 | 152-177 | |
BMI (kg/m2) | 0.291 | |||
Mean (SD) | 22.37 (2.40) | 23.00 (2.56) | 22.68 (2.48) | |
Range | 17.3-28.8 | 17.3-28.3 | 17.3-28.8 |
Table 2 Descriptive statistics for abdominal pain at visit 2 and visit 4
Sequence | n | Period 1 | Period 2 | |||
Mean | SD | Mean | SD | |||
Abdominal pain | KP | 32 | 1.4688 | 0.87931 | 6.2188 | 2.4591 |
PK | 33 | 7.2121 | 2.342 | 1.6667 | 1.0206 |
Table 3 Cross-over effects and analysis details for abdominal pain
Effect | SE | DF | T value | P value | 95%CI | Significance | |
Carryover | -1.1913 | 0.69641 | 63 | -1.7106 | 0.092 | -2.5830, 0.20038 | No |
Treatment | -5.1477 | 0.28995 | 63 | -17.754 | 0.000 | -5.7271, -4.5683 | Yes |
Period | -0.39773 | 0.28995 | 63 | -1.3717 | 0.175 | -0.97714, 0.18169 | No |
Table 4 Descriptive statistics for abdominal bloating at visit 2 and visit 4
Sequence | n | Period 1 | Period 2 | |||
Mean | SD | Mean | SD | |||
Abdominal bloating | KP | 32 | 1.3125 | 0.7378 | 4.9375 | 1.7949 |
PK | 33 | 5.4848 | 1.8392 | 1.4545 | 0.66572 |
Table 5 Cross-over effects and analysis details for abdominal blotting
Effect | SE | DF | T value | P value | 95%CI | Significance | |
Carryover | -0.68939 | 0.50583 | 63 | -1.3629 | 0.178 | (-1.7002, 0.32143) | No |
Treatment | -3.8277 | 0.22994 | 63 | -16.646 | 0.000 | (-4.2872, -3.3681) | Yes |
Period | -0.20265 | 0.22994 | 63 | -0.88131 | 0.382 | (-0.66216, 0.25686) | No |
Table 6 T-test for abdominal pain and abdominal bloating (one-sided)
Mean (KiwiBiotic) | Mean (Psyllium husk) | SE | DF | T value | P value | Significance | |
Abdominal pain | 1.5692 | 6.7231 | 0.28995 | 63 | -17.754 | < 0.05 | Yes |
Abdominal bloating | 1.3846 | 5.2154 | 0.22994 | 63 | -16.646 | < 0.05 | Yes |
Table 7 Assessment of functional constipation
Symptoms of functional constipation | Number of subjects experiencing symptom relief from functional constipation after consuming KiwiBiotic but not after psyllium husk | Number of subjects experiencing symptom relief from functional constipation after consuming psyllium husk but not after KiwiBiotic | P value for MC-Nemar’s test |
Straining during more than ¼ 25% of excretion | 39 | 1 | < 0.05 |
Lumpy or hard stools (BSFS type 1 or 2) more than 25% of defecations | 39 | 1 | < 0.05 |
Sensation of incomplete evacuation of more than one-fourth (25%) of defecations | 37 | 1 | < 0.05 |
Sensation of anorectal obstruction/blockage more than ¼ (25%) of defecations | 33 | 0 | < 0.05 |
Manual manoeuvres to facilitate more than ¼ (25%) of defecation | 33 | 1 | < 0.05 |
Fewer than three spontaneous bowel movements per week | 11 | 2 | < 0.05 |
Table 8 Percentage of subjects improved their symptoms of functional constipation
Symptoms of functional constipation | After the KiwiBiotic treatment (%) | After the psyllium husk treatment (%) |
Straining during more than ¼ 25% of excretion | 91.0 | 32.0 |
Lumpy or hard stools (BSFS type 1 or 2) more than 25% of defecations | 91.0 | 32.0 |
Sensation of incomplete evacuation of more than one-fourth (25%) of defecations | 91.0 | 35.0 |
Sensation of anorectal obstruction/blockage more than ¼ (25%) of defecations | 95.0 | 45.0 |
Manual manoeuvres to facilitate more than ¼ (25%) of defecation | 94.0 | 45.0 |
Fewer than three spontaneous bowel movements per week | 97.0 | 83.0 |
Table 9 Effect of treatments on gastrointestinal quality of life index and its domain and estimation for paired differences (two-sided)
KiwiBiotic | Psyllium-husk | |||||
Estimation for paired difference | ||||||
GIQLI domains | Mean (SD) | 95%CI | P value | Mean (SD) | 95%CI | P value |
GI-symptoms | -39.69 (6.3) | -41.264, -38.121 | < 0.05 | -10.78 (15.7) | -14.67, -6.90 | < 0.05 |
Psychological | -10.19 (2.2) | -10.744, -9.626 | < 0.05 | -0.415 (5.5) | -1.787, 0.956 | 0.547 |
Physical | -16.71 (3.3) | -17.533, -15.883 | < 0.05 | -3.23 (7.1) | -4.999, -1.463 | 0.001 |
Social | -2.37 (3.6) | -3.262, -1.476 | < 0.05 | -0.077 (2.0) | -0.571, 0.417 | 0.757 |
Overall | -68.95 (10.5) | -71.56, -66.35 | < 0.05 | -14.51 (26.8) | -21.15, -7.86 | < 0.05 |
Table 10 Overall treatment evaluation score
Condition | KiwiBiotic (%) | Psyllium-husk |
Resolved | 55.38 | 0.00 |
Much better | 41.54 | 9.23 |
Little better | 3.08 | 13.85 |
The same | 0.00 | 33.85 |
Worse | 0.00 | 43.08 |
- Citation: Porwal AD, Gandhi PM, Kulkarni DK, Bhagwat GB, Kamble PP. Effect of KiwiBiotic on functional constipation and related symptoms: A prospective, single-center, randomized, comparative, crossover study. World J Gastrointest Pharmacol Ther 2024; 15(5): 97330
- URL: https://www.wjgnet.com/2150-5349/full/v15/i5/97330.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v15.i5.97330